Wellbeing Digital Sciences Aktie

Wellbeing Digital Sciences Inc (NEO:MEDI.AQN, OTCQB:KONEF) told investors it has struck a deal to sell its wholly-owned KGK Science subsidiary to Cardinal Group Inc for $2 million.  The company said in a statement that Cardinal has advanced a non-refundable deposit of $200,000 under the share purchase agreement dated June 7, 2023, with further deposits to be advanced at its discretion before the completion of the transaction, subject to Wellbeing's approval.» Mehr auf proactiveinvestors.com

Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) reported that its subsidiary KGK Science on behalf of its client Nova Mentis has commenced patient recruitment for its first-of-its-kind, Health Canada-approved clinical trial investigating psilocybin in adults diagnosed with fragile X syndrome (FXS). The Phase 2a trial, being conducted at KGK's facility in London, Ontario, will test the safety and efficacy of Nova Mentis' psilocybin drug NM-1001 for FXS, which is a leading genetic cause of autism spectrum disorder.» Mehr auf proactiveinvestors.com

Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) announced that its wholly-owned KGK Sciences Inc (KGK) subsidiary has applied for a Controlled Substance Dealers License from Health Canada, which would allow KGK to possess, import, sell and study several controlled substances including psilocybin, LSD, DMT, ketamine and MDMA. The mental healthcare company also said KGK has received approval to proceed with the buildout of a level 5 security system at its state-of-the-art research facility in London, Ontario.» Mehr auf proactiveinvestors.com